The second annual report from Kalderos leverages trade analysis and inside information to current a holistic perspective on the implications of pharma’s “recognized unknowns”
CHICAGO, April 13, 2022 /PRNewswire/ — Well being tech firm Kalderos, maker of a data-driven platform for Drug Low cost Administration, immediately launched its 2022 annual report, outlining a imaginative and prescient for tech-enabled platform options to raised serve sufferers.
In its second 12 months, the Kalderos annual report illuminates how systemic information gaps have undermined efforts to make prescribed drugs extra inexpensive and explains why these information gaps problem each healthcare stakeholder.
“Our second annual report discusses a subject that is of the best significance to us at Kalderos: how higher information unites stakeholders to unravel systemic challenges and in the end make the healthcare system work extra successfully for sufferers,” mentioned Kalderos CEO Brent Dover. “As we quickly scale our platform for Drug Low cost Administration, our report highlights the necessity for correct information and technological infrastructure to allow collaborative problem-solving.”
The Kalderos 2022 annual report identifies plenty of challenges that contribute to excessive drug costs and suggests alternatives to beat them. Leveraging inside information and complete trade analysis and evaluation, the report discusses:
- How the pervasive absence of key information continues so as to add value and complexity to a system that has been hindered by a scarcity of transparency
- The affect that information gaps have on every healthcare stakeholder, together with drug producers, suppliers, payers and sufferers
- How lack of actionable information thwarts policymakers’ efforts to make prescribed drugs extra inexpensive
The report leverages Kalderos’ inside and proprietary information to take a better take a look at one information hole particularly – the unknown extent and affect of noncompliant reductions. The Kalderos platform incorporates the nation’s largest confirmed dataset of duplicate reductions between Medicaid and the 340B Drug Pricing Program, enabling distinctive evaluation.
This 12 months’s report contains an up to date projection for the overall variety of duplicate reductions for 2020, through which the price of these duplicate reductions – that are prohibited by legislation – reached a minimum of $1.3 billion to $2.1 billion, a rise of roughly 35% over 2019.
The 2022 Kalderos annual report additionally makes use of information to light up the variability of a person drug producer’s publicity to noncompliance. Taking an combination of a number of drug producers, Kalderos’ tech-enabled, data-driven method recognized practically 10 instances as a lot noncompliance as producers’ present strategies.
“Once we based Kalderos, we needed to leverage a very distinctive method to Drug Low cost Administration, and it is empowering to see the affect we have had on the trade so far,” mentioned Jeremy Docken, founder and chief technique officer for Kalderos. “Our second annual report represents one other milestone in our firm’s journey, and we look ahead to new alternatives transferring ahead.”
Kalderos skilled accelerated development in 2021, together with a 200% improve in prospects and a 300% improve in income. The corporate additionally deepened its concentrate on operations and commercialization, constructing groups and implementing processes to speed up additional this 12 months.
In February, Built In chose Kalderos as one of “22 Chicago startups to watch in 2022.” Additionally in February, the company named seasoned health tech executive Brent Dover as its new Chief Executive Officer.
Entitled “Conquering the ‘Great Unknown’: Connecting the data gaps that keep us from knowing the true price of drugs,” Kalderos’ second annual report is offered now in net and PDF variations.
Kalderos created the world’s first Drug Low cost Administration platform, which makes use of subtle fashions and machine studying to resolve noncompliance points in drug low cost packages. The corporate’s options embody Low cost Monitoring, which leverages a predictive mannequin to determine and resolve historic situations of noncompliance, and 340B Pay, the primary real-time resolution for drug low cost effectuation, which permits suppliers of any measurement to request 340B rebates and producers to confirm and pay them by way of a 3rd occasion fee accomplice. Primarily based in Chicago, Kalderos was based in 2016 by a workforce devoted to decreasing inefficiencies within the U.S. healthcare system, empowering everybody to concentrate on the well being of individuals. Extra data will be discovered at www.kalderos.com.